Nektar Therapeutics (NASDAQ:NKTR) Receives $111.83 Consensus PT from Analysts

Nektar Therapeutics (NASDAQ:NKTR) has received a consensus rating of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $110.8571.

A number of equities research analysts have recently commented on NKTR shares. Jefferies Financial Group reiterated a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, December 17th. HC Wainwright upped their price objective on Nektar Therapeutics from $120.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Piper Sandler reissued an “overweight” rating and issued a $105.00 target price on shares of Nektar Therapeutics in a report on Monday. Citigroup began coverage on Nektar Therapeutics in a report on Wednesday, November 26th. They set a “buy” rating and a $102.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nektar Therapeutics in a research report on Monday, December 29th.

Nektar Therapeutics Stock Performance

NKTR opened at $37.18 on Friday. The stock has a market capitalization of $756.24 million, a PE ratio of -4.67 and a beta of 1.31. The stock’s 50 day moving average price is $48.01 and its 200-day moving average price is $44.88. Nektar Therapeutics has a 52-week low of $6.45 and a 52-week high of $66.92.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.85) by $1.00. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%. The company had revenue of $11.79 million for the quarter, compared to analysts’ expectations of $10.20 million. Research analysts forecast that Nektar Therapeutics will post -0.72 EPS for the current fiscal year.

Insider Buying and Selling

In other Nektar Therapeutics news, insider Jonathan Zalevsky sold 3,867 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total transaction of $137,935.89. Following the completion of the sale, the insider directly owned 21,354 shares of the company’s stock, valued at approximately $761,697.18. This represents a 15.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Howard W. Robin sold 2,207 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $54.28, for a total transaction of $119,795.96. Following the completion of the transaction, the chief executive officer owned 54,245 shares in the company, valued at $2,944,418.60. The trade was a 3.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 7,861 shares of company stock valued at $354,730 over the last 90 days. Company insiders own 3.71% of the company’s stock.

Institutional Trading of Nektar Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its holdings in shares of Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 210 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of Nektar Therapeutics in the second quarter worth about $39,000. Compass Wealth Management LLC bought a new position in Nektar Therapeutics during the third quarter valued at approximately $88,000. Bessemer Group Inc. grew its holdings in Nektar Therapeutics by 1,741.2% during the 3rd quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 1,480 shares in the last quarter. Finally, Bayforest Capital Ltd bought a new stake in Nektar Therapeutics in the 3rd quarter worth approximately $96,000. 75.88% of the stock is owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.